Echocardiographic predictors of outcomes in hypertrophic cardiomyopathy-Reference-Cited by-同舟云学术

Echocardiographic predictors of outcomes in hypertrophic cardiomyopathy

Published:2023-10-31 Issue:2 Volume:1 Page:88-102
ISSN:
Container-title:Exploration of Cardiology
language:
Short-container-title:Explor Cardiol

Author:

Franco Annamaria Del¹^ORCID,Pálinkás Eszter Dalma²^ORCID,Panichella Giorgia¹^ORCID,Olivotto Iacopo³^ORCID

Affiliation:

1. Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy

2. Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy; Doctoral School of Clinical Medicine, University of Szeged, 6720 Szeged, Hungary

3. Cardiology Unit, IRCCS Meyer Children’s Hospital, 50139 Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy

Abstract

The use of echocardiography, a straightforward and widely available technique, allows for a comprehensive assessment of the patient with hypertrophic cardiomyopathy (HCM) under both resting and stress conditions. The true prevalence of HCM has been redefined over time by this imaging approach, which has also made it feasible to pinpoint parameters that clinicians may use to stratify patients at risk for adverse cardiovascular events. The current and emerging prognostic predictors in HCM, assessed with transthoracic echocardiography at rest and during provocation, are discussed in this review.

Publisher

Open Exploration Publishing

Subject

Ocean Engineering,General Earth and Planetary Sciences,General Engineering,General Environmental Science,General Medicine,Development,Geography, Planning and Development,General Earth and Planetary Sciences,General Environmental Science,Materials Chemistry

Reference68 articles.

1. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915–28.

2. Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.

3. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients With hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020;142:e558–631.

4. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778–85.

5. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–41.